MedPath

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. logo
🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:3
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (75.0%)
Phase 2
1 (25.0%)

A Study of QY101 Ointment in Subjects With Plaque Psoriasis

Phase 2
Recruiting
Conditions
Psoriasis
Interventions
Drug: QY101Placebo/QY101 ointment
First Posted Date
2023-12-14
Last Posted Date
2023-12-19
Lead Sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Target Recruit Count
160
Registration Number
NCT06170840
Locations
🇨🇳

Shanghai Skin Disease Hospital, Shanghai, Shanghai, China

A First-in-Human Study of QY211 Gel in Adult Subjects

Phase 1
Recruiting
Conditions
Atopic Dermatitis
Interventions
Drug: 0.8% QY211 Gel or placebo
Drug: 1.5% QY211 Gel or placebo
Drug: 0.1% QY211 Gel or placebo
Drug: 0.3% QY211 Gel or placebo
First Posted Date
2023-05-06
Last Posted Date
2023-05-06
Lead Sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Target Recruit Count
56
Registration Number
NCT05843422
Locations
🇨🇳

Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis

Phase 1
Not yet recruiting
Conditions
Atopic Dermatitis
Interventions
Drug: 5mg QY201 tablets or 5mg QY201 placebo,BID
Drug: 2mg QY201 tablets or 2mg QY201 placebo,BID
Drug: 20mg QY201 tablets,BID
Drug: QY201 placebo,BID
Drug: 10mg QY201 tablets,BID
Drug: 10mg QY201 tablets or 10mg QY201 placebo,QD
Drug: 10mg QY201 tablets or 10mg QY201 placebo,BID
Drug: 15mg QY201 tablets or 15mg QY201 placebo,BID
Drug: 20mg QY201 tablets or 20mg QY201 placebo,BID
Drug: 5mg QY201 tablets,BID
First Posted Date
2022-09-02
Last Posted Date
2022-09-02
Lead Sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Target Recruit Count
260
Registration Number
NCT05525715

A First-in-Human Study of QY101 Ointment in Adult Subjects

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: QY101 ointment or vehicle
First Posted Date
2022-06-23
Last Posted Date
2023-09-25
Lead Sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Target Recruit Count
77
Registration Number
NCT05429177
Locations
🇨🇳

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

News

No news found
© Copyright 2025. All Rights Reserved by MedPath